Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof
Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
1. An unsolvated crystal form of the compound of Formula (I):
which is enantiomerically pure, wherein the crystal form is Form A, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 14.4, 17.4, 23.6 and 25.1 degrees 2θ, or Form F, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 15.6, 17.3, and 25.4 degrees 2θ.
2. The crystal form of claim 1 , wherein the crystal form is Form A, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 14.4, 17.4, 23.6 and 25.1 degrees 2θ.
3. The crystal form of claim 1 , wherein the crystal form is Form A, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 14.4, 15.2, 17.4, 18.4, 19.2, 20.5, 22.8, 23.2, 23.6, 24.5 and 25.1 degrees 2θ.
4. The crystal form of claim 1 , wherein the crystal form is Form A, which has an X-ray powder diffraction pattern matching the pattern depicted in FIG. 1 .
5. The crystal form of claim 1 , wherein the crystal form is Form A, which has a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 155° C.
6. The crystal form of claim 1 , wherein the crystal form is Form A, which has a differential scanning calorimetry plot matching the plot depicted in FIG. 2 .
7. The crystal form of claim 1 , wherein the crystal form is Form A, which has a thermal gravimetric analysis plot comprising a mass loss of less than about 1% when heated from about 25° C. to about 140° C.
8. The crystal form of claim 7 , wherein the mass loss is about 0.05%.
9. The crystal form of claim 1 , wherein the crystal form is Form A, which has a thermal gravimetric analysis plot matching the plot depicted in FIG. 3 .
10. The crystal form of claim 1 , wherein the crystal form is Form A, which exhibits a mass increase of less than about 1% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.
11. The crystal form of claim 10 , wherein the mass increase is about 0.4%.
12. The crystal form of claim 1 , wherein the crystal form is Form A, which has a moisture sorption isotherm plot matching the plot depicted in FIG. 4 .
13. The crystal form of claim 1 , wherein the crystal form is Form A, which is stable upon exposure to about 40° C. and about 75% relative humidity for about 4 weeks.
14. The crystal form of claim 1 , wherein the crystal form is Form F, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 15.6, 17.3 and 25.4 degrees 2θ.
15. The crystal form of claim 1 , wherein the crystal form is Form F, which has an X-ray powder diffraction pattern comprising peaks at about 8.1, 8.6, 15.6, 17.3, 19.3, 21.4, 22.8, 24.6, 25.4, 25.9, 26.6 and 27.7 degrees 2θ.
16. The crystal form of claim 1 , wherein the crystal form is Form F, which has an X-ray powder diffraction pattern matching the pattern depicted in FIG. 21 .
17. The crystal form of claim 1 , wherein the crystal form is Form F, which has a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 145° C.
18. The crystal form of claim 1 , wherein the crystal form is Form F, which has a differential scanning calorimetry plot matching the plot depicted in FIG. 22 .
19. The crystal form of claim 1 , wherein the crystal form is Form F, which has a thermal gravimetric analysis plot comprising a mass loss of less than about 1% when heated from about 25° C. to about 180° C.
20. The crystal form of claim 19 , wherein the mass loss is about 0.1%.
21. The crystal form of claim 1 , wherein the crystal form is Form F, which has a thermal gravimetric analysis plot matching the plot depicted in FIG. 23 .
22. The crystal form of claim 1 , wherein the crystal form is Form F, which exhibits a mass increase of less than about 1% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.
23. The crystal form of claim 22 , wherein the mass increase is about 0.2%.
24. The crystal form of claim 1 , wherein the crystal form is Form F, which has a moisture sorption isotherm plot matching the plot depicted in FIG. 24 .
25. The crystal form of claim 1 , wherein the crystal form is Form F, which is stable upon exposure to about 40° C. and about 75% relative humidity for about 4 weeks.
26. The crystal form of claim 1 , which is substantially pure.
27. A solid pharmaceutical composition comprising the crystal form of claim 2 .
28. The crystal form of claim 1 , which is anhydrous.
29. The crystal form of claim 1 , which contains less than about 10 percent by weight of one or more other solid forms or other chemical compounds.
30. The crystal form of claim 1 , which contains less than about 5 percent by weight of one or more other solid forms or other chemical compounds.
31. A pharmaceutical composition suitable for oral administration, comprising about 1 mg to about 200 mg of the crystal form of claim 1 .
32. The pharmaceutical composition of claim 31 , wherein the pharmaceutical composition comprises about 10 mg to about 100 mg of the crystal form.
33. The pharmaceutical composition of claim 31 , wherein the pharmaceutical composition is in capsule form.
34. The pharmaceutical composition of claim 33 , wherein the capsule contains about 10 mg of the compound.
35. The pharmaceutical composition of claim 33 , wherein the capsule contains about 20 mg of the compound.
36. The pharmaceutical composition of claim 33 , wherein the capsule contains about 25 mg of the compound.
37. The pharmaceutical composition of claim 33 , wherein the capsule contains about 50 mg of the compound.
38. The pharmaceutical composition of claim 31 , wherein the pharmaceutical composition is in tablet form.
39. The pharmaceutical composition of claim 38 , wherein the tablet contains about 10 mg of the compound.
40. The pharmaceutical composition of claim 38 , wherein the tablet contains about 20 mg of the compound.
41. The pharmaceutical composition of claim 38 , wherein the tablet contains about 25 mg of the compound.
42. The pharmaceutical composition of claim 38 , wherein the tablet contains about 50 mg of the compound.